Title:
前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
Document Type and Number:
Japanese Patent JP7142957
Kind Code:
B2
Abstract:
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumorassociated T-cell peptide epitopes, alone or in combination with other tumorassociated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Inventors:
Andrea, Mare
Weinschenk, Toni
Shall, Oliver
Fritche, jens
Shin, Harpreet
Muller, Philip
Leibold, Yulia
Goldfinger, valentina
Weinschenk, Toni
Shall, Oliver
Fritche, jens
Shin, Harpreet
Muller, Philip
Leibold, Yulia
Goldfinger, valentina
Application Number:
JP2020191407A
Publication Date:
September 28, 2022
Filing Date:
November 18, 2020
Export Citation:
Assignee:
Immatics Biotechnology Gem Beher
International Classes:
C12N15/12; A61K9/08; A61K9/10; A61K9/19; A61K31/7088; A61K35/12; A61K35/17; A61K38/08; A61K39/00; A61K39/395; A61K48/00; A61P35/00; C07K7/06; C07K14/47; C07K16/18; C07K19/00; C12N5/0783; C12N5/10; C12N15/09; C12N15/115; C12N15/13; C12N15/62; C12N15/63; C12P21/02
Domestic Patent References:
| JP2014502961A | ||||
| JP2012504393A | ||||
| JP6884752B2 | ||||
| JP2004504808A |
Foreign References:
| WO2011119484A1 | ||||
| WO2013040142A2 |
Other References:
PLoS One, 2012.09.20, vol. 7, no. 9, article no. e45756 (pp. 1-9)
Attorney, Agent or Firm:
Takashi Shoji